CTRI/2016/12/007543已完成未知
A Multicenter, randomized, single-blind, 2-way crossover, Pivotal Pharmacokinetic Bioequivalence Study Comparing Generic to Reference Liposome-Encapsulated Doxorubicin Hydrochloride in Subjects with Epithelial Ovarian Carcinoma Who Have Failed Platinum-Based Chemotherapy
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- TOLMAR Inc
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Female between 18 and 75 years of age, inclusive.
- •2.Histologically proven epithelial ovarian carcinoma.
- •3.Documented progressive or recurrent disease after treatment with platinum based chemotherapy.
- •4.Able and clinically indicated to receive liposomal doxorubicin HCl, as specified in the DOXOrubicin Package Insert for subjects with ovarian cancer, without exceeding a lifetime cumulative dosage of 450 mg/m2 (See Section 7.3.1 for rationale). Prior use of conventional or liposomal doxorubicin formulations, in addition to the use of other anthracyclines or anthracenediones should be included in calculations of total lifetime cumulative dose.
- •5.Able and clinically indicated to receive the recommended minimum 4 courses of liposomal doxorubicin HCl either during participation in this study, including infusions prior to enrolling in this study or after completing study participation
- •6.Eastern Cooperative Oncology Group (ECOG) performance status of <= 2 (See Appendix 14.1). Any subject who experiences deterioration in ECOG status to 4 during the study should discontinue participation in the study.
- •7.Life expectancy of > 180 days.
- •8.Acceptable hematology status:
- •a.Hemoglobin >= 9 g/dL
- •b.Absolute neutrophil count (ANC) >= 1500 cells/µL
- •c.Platelet count >= 75,000 cells/µL
- •9.Acceptable liver function:
- •a.Alanine aminotransferase (ALT) <= 2X upper limit of normal (ULN)
- •b.Aspartate aminotransferase (AST) <= 2X ULN
- •c.Bilirubin < 1.2 mg/dL
- •d.Alkaline phosphatase <= 2X ULN
- •10.Acceptable kidney function
- •a.Creatinine <= 2X ULN or
- •b.Creatinine clearance >= 60 mL/minute
- •11.Cardiac ejection fraction >= 50% by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within 14 days prior to first dose of Investigational Product.
- •12.If of childbearing potential, must agree to use adequate contraception (eg, hormonal, chemical, double-barrier, or abstinence) while on study and for 3 months after study participation is discontinued.
- •13.Willing and able to provide written informed consent prior to any study-related activities being performed.
排除标准
- •Exclusion Criteria:
- •1.Received liposomal doxorubicin HCl in the past and had a required dose reduction to below 50 mg/m2, or whose disease has progressed or recurred after treatment with liposomal doxorubicin.
- •2.Received previous chemotherapy less than 4 weeks prior to dosing of Investigational Product.
- •3.Recent (6 month) history of myocardial infarction or severe arrhythmias prior to dosing of Investigational Product (See DOXOrubicin Package Insert).
- •4.History of major cardiac (New York Heart Association [NYHA] Type III or IV), liver, or kidney disease.
- •5.Received any prior mediastinal irradiation (as cardiac toxicity may occur at lower cumulative doses).
- •6.Receipt of trastuzumab within 24 weeks prior to dosing of Investigational Product and during the study (DOXOrubicin Hydrochloride Injection Package Insert).
- •7.Receipt of cyclophosphamide, calcium channel blockers, and other potential cardiotoxic drugs for 2 weeks prior to dosing of Investigational Product, and during the study (See DOXOrubicin Package Insert and anthracycline package insert).
- •8.Receipt of phenytoin for 2 weeks prior to dosing of Investigational Product, and during the study as phenytoin levels may be decreased by doxorubicin (See DOXOrubicin Hydrochloride Injection Package Insert).
- •9.Known hypersensitivity, idiosyncratic, or allergic reactions to conventional or liposomal formulations of doxorubicin, anthracycline therapy or to any of their components.
- •10.Pregnant or breastfeeding.
- •11.Active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii, or other microorganism.
- •12.Presence or recent history (within the last 2 months) of clinically significant ascites requiring intervention (eg, paracentesis).
- •Note: stable dose of diuretics will be permitted.
- •13.Known central nervous system metastasis.
- •14.Major surgical procedure (including periodontal) within 28 days of first dose of Investigational Product.
- •15.Surgical or other non-healing wounds.
- •16.Exposure to any investigational agent within 28 days prior to first dose of Investigational Product.
- •17.History of other malignancies in the last 5 years. Potential subjects with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Potential subjects with other malignancies that were cured with definitive primary therapy alone (eg, surgery) and who have been continuously free of the previous disease for 1 year are also eligible upon Sponsor approval.
- •18.Severe or life-threatening infection, including known past medical history of human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).
- •19.Has not recovered to Grade 0 or 1 toxicity from previous anticancer treatments or previous investigational agents. Exceptions are alopecia (any grade is acceptable), fatigue (Grade 2 is acceptable), and peripheral neuropathy (stable Grade 2 is acceptable) (Per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], v4.03).
- •20.Uncontrolled diabetes mellitus.
- •21.Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requir
研究者
相似试验
已完成
3 期
A clinical trial to study the effects of two drugs Adapalene and Benzyl peroxide topical gen in patients with mild to moderate with facial acne vulgaris.CTRI/2019/12/022244BELUPO Pharmaceuticals and Cosmetics Incorporated650
已完成
不适用
A multi-center, single-blinded, randomized, controlled, parallel-group study to evaluate the wearing comfort of two different placebo intrauterine systems FR01 and FR20 compared to a placebo T-frame intrauterine system for 3 cycles in healthy women aged 18-40 yearsdraagcomfort en insertie/verwijdering van IUSinsertion/removalwearing comfortNL-OMON32633Bayer40
进行中（未招募）
不适用
A single-centre, randomised, double-blind, cross-over trial comparing the within-subject variability of the pharmacokinetic profiles of insulin detemir and insulin glargine in children and adolescents with type 1 diabetesType I DiabetesMedDRA version: 7.0Level: PTClassification code 10012608EUCTR2004-001692-19-DEovo Nordisk AS
已完成
4 期
A multi-center, randomized, double-blind, double-simulated, positive drug parallel controlled clinical trial to evaluate the effectiveness and safety of Jiuwei Zhenxin Granules in the treatment of generalized anxiety disorderGeneralized Anxiety DisorderITMCTR2100004826Beijing Anding Hospital, Capital Medical University
尚未招募
4 期
A multi-center, randomized, double-blind, double-simulated, and positive-drug parallel-controlled clinical study to evaluate the effectiveness and safety of Quanduzhong capsule in treating essential hypertension&Essential hypertension (nephrasthenia syndrome)ITMCTR2100004710Beijing Hospital of Traditional Chinese Medicine